

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Pera et al.)	Examiner:
)	Michail A. Belyavskyi
Serial No.	:	10/574,885)	
)	
Filed	:	October 8, 2004)	Art Unit:
)	1644
Conf. No.	:	3366)	
)	
For	:	CELL SURFACE MARKER)	
)	

REQUEST FOR RECONSIDERATION

Mail Stop AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DO NOT ENTER: /M.B./

DO NOT ENTER: /M.B./

Dear Sir:

In response to the final office action mailed January 12, 2010, reconsideration is respectfully requested.

The rejection of claims 109-113 and 115-121 under 35 U.S.C. § 102(a) as anticipated by Schopperle et al., "Human Embryonal Carcinoma Tumor Antigen, GP200/GCTM-2, is Podocalyxin," *Biochemical and Biophysical Research Communications* 300:285-290 (2003) ("Schopperle") is respectfully traversed.

Schopperle reports that a peanut agglutinin-binding tumor antigen, gp200, a surface membrane glycoprotein expressed on human embryonal carcinoma, a malignant stem cell of testicular tumors, is similar to another embryonal carcinoma antigen, GCTM-2. GCTM-2 is a cell differentiation marker that is also detected in blood of testis cancer patients.

It is the position of the U.S. Patent and Trademark Office ("PTO") that while Schopperle is silent with respect to a detector that binds to a stem cell marker characterized by binding to a GCTM-5 antibody, the antibodies recognized antigens derived from membrane